Evaluation of HER2 containing dimerzation for prediction of HER2-targeting therapy
| Project/Area Number |
25861155
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 乳癌 / HER2 / 二量体 / breast cancer / predictive factor |
|---|
| Outline of Final Research Achievements |
The expression levels of HER2-containing dimer were evaluated in series of HER2-positive breast cancer cell lines. We also evaluated the association between expression of HER2-containing dimer and trastuzumab-sensitivity in breast cancer patients who underwent trastuzumab-containing neoadjuvant chemotherapy. HER2-containing dimer was evaluated by proximity ligation assays. There were higher expression levels of HER2-2 dimer in trastuzumab-sensitive cell lines compared to the resistant cell lines (sensitive vs. resistant, 65 vs. 15, p<0.01). In a cohort of 23 HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy, high HER2-2 dimer expression cohort showed significantly higher rate of quasi-pathological complete response compared with low HER2-2 dimer expression cohort (high vs. low, 26/37, 70% vs. 2/11, 18%, p=0.006).
|
Report
(3 results)
Research Products
(6 results)
